NasdaqGS:NUVLBiotechs
Assessing Nuvalent (NUVL) Valuation As A High P/B And DCF Gap Shape Expectations
Nuvalent (NUVL) has drawn investor attention as a clinical stage cancer drug developer with no current revenue, a reported net loss of US$381.435 million, and a share price of US$103.59.
See our latest analysis for Nuvalent.
Recent trading has been mixed, with a 2.67% 1 day share price return and an 11.41% 90 day share price return. The 1 year total shareholder return of 20.90% and 3 year total shareholder return of about 3.6x indicate that longer term momentum has been much stronger than...